Efficacy and safety of a novel antiviral preparation in ICU-admitted patients with COVID-19: a phase III randomized controlled trial
Hossein Faramarzi, Amirhossein Sahebkar, Ahmad Hosseinpour, Vahid Khaloo, Parisa Chamanpara, Mohammad Reza Heydari, Sajad Najafi, Fatemeh Fotoohi Khankahdany, Ahmad Movahedpour
doi: https://doi.org/10.1101/2021.11.20.21266229
Hossein Faramarzi
1Department of Community Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
M.D.Amirhossein Sahebkar
2Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
3Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Pharm.D., Ph.D.Ahmad Hosseinpour
4Shimi Teb Salamat Co., Shiraz, Iran
M.Sc.Vahid Khaloo
5Ali Asghar Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
M.D.Parisa Chamanpara
6Department of Biostatistics, Shiraz University of Medical Sciences, Shiraz, Iran
Ph.D.Mohammad Reza Heydari
7Shiraz HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran
Pharm.D., Ph.D.Sajad Najafi
8Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Ph.D.Fatemeh Fotoohi Khankahdany
4Shimi Teb Salamat Co., Shiraz, Iran
M.Sc.Ahmad Movahedpour
9Behbahan Faculty of Medical Sciences, Behbahan, Iran
Ph.D.Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Posted November 23, 2021.
Efficacy and safety of a novel antiviral preparation in ICU-admitted patients with COVID-19: a phase III randomized controlled trial
Hossein Faramarzi, Amirhossein Sahebkar, Ahmad Hosseinpour, Vahid Khaloo, Parisa Chamanpara, Mohammad Reza Heydari, Sajad Najafi, Fatemeh Fotoohi Khankahdany, Ahmad Movahedpour
medRxiv 2021.11.20.21266229; doi: https://doi.org/10.1101/2021.11.20.21266229
Efficacy and safety of a novel antiviral preparation in ICU-admitted patients with COVID-19: a phase III randomized controlled trial
Hossein Faramarzi, Amirhossein Sahebkar, Ahmad Hosseinpour, Vahid Khaloo, Parisa Chamanpara, Mohammad Reza Heydari, Sajad Najafi, Fatemeh Fotoohi Khankahdany, Ahmad Movahedpour
medRxiv 2021.11.20.21266229; doi: https://doi.org/10.1101/2021.11.20.21266229
Subject Area
Subject Areas
- Addiction Medicine (372)
- Allergy and Immunology (690)
- Anesthesia (184)
- Cardiovascular Medicine (2755)
- Dermatology (235)
- Emergency Medicine (414)
- Epidemiology (12403)
- Forensic Medicine (10)
- Gastroenterology (784)
- Genetic and Genomic Medicine (4263)
- Geriatric Medicine (396)
- Health Economics (699)
- Health Informatics (2758)
- Health Policy (1020)
- Hematology (370)
- HIV/AIDS (880)
- Medical Education (404)
- Medical Ethics (112)
- Nephrology (454)
- Neurology (4043)
- Nursing (216)
- Nutrition (600)
- Oncology (2129)
- Ophthalmology (604)
- Orthopedics (251)
- Otolaryngology (313)
- Pain Medicine (256)
- Palliative Medicine (77)
- Pathology (478)
- Pediatrics (1149)
- Primary Care Research (470)
- Public and Global Health (6653)
- Radiology and Imaging (1446)
- Respiratory Medicine (886)
- Rheumatology (421)
- Sports Medicine (353)
- Surgery (464)
- Toxicology (57)
- Transplantation (192)
- Urology (171)